Type 2 diabetes
Conditions
Interventions
Administration of mitiglinide/voglibose combination (twice daily)
Administration of glinide or alpha-GI (thrice daily)
Sponsors
Juntendo University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)The patients treated with diet therapy and glinide or alpha-GI of fixed dosage and administrated for eight weeks or longer before start of observation period. 2)The patients who can take fixed dosage and same medicine during the study, in case of being treated with combination therapy of oral hypoglycemic agents other than glinide or alpha-GI for eight weeks or longer before start of observation period. 3)The patients with HbA1c(NGSP) less than 8.4% (start of observation period and start of treatment period). 4)The patients who can measure SMBG. 5)The patients whose age are more than 20 years. 6)Outpatients.
Exclusion criteria
Exclusion criteria: 1)The patients applicable to the contraindications of mitiglinide or voglibose. 2)The patients who are treated with combination therapy of gulinide and alpha-GI. 3)The patients who has an administration history of SU drug within eight weeks before start of observation period. 4)The patients who drink alcohol too much. 5)The patients complicated with severe diabetic microangiopathy. 6)The patients complicated with severe hepatic diseases or severe renal diseases. 7)The patients complicated with severe cardiac disease. 8)The patients complicated with severe hypertension. 9)The patients who are treated with GLP-1 analog or insulin, or the patients who need their treatment. 10)In addition, the patients whom researchers judged to be inappropriate to study participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes of HbA1c (NGSP) from baseline | — |
Countries
Japan
Outcome results
None listed